Latest Actavis Stories

PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy. The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. The...

PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has cancelled its appearance at the upcoming Bank of America Merrill Lynch Healthcare Conference. Actavis had been scheduled to present on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. About Actavis, Inc. Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company...

PARSIPPANY, N.J., May 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has entered into early stage discussions with Warner Chilcott plc (Nasdaq: WCRX) regarding a potential combination of the two companies. Actavis further stated that no agreement has been reached and it does not intend to issue further comment regarding its business development initiatives. About Actavis, Inc. Actavis, Inc. (NYSE: ACT)...

PARSIPPANY, N.J., May 7, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on...

PARSIPPANY, N.J., May 3, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), today announced that the Company will host its 2013 Annual Meeting of Stockholders on Friday, May 10, 2013 beginning at 8:30 AM Eastern Daylight Time. The meeting will be held at the Parsippany Sheraton in Parsippany, NJ, and will be open to in-person stockholders of record only. Actavis will not be providing a formal update on the business at the meeting, but rather will consider and vote on certain routine...

- 21% Increase in Q1 2013 Non-GAAP EPS to $1.99; GAAP Earnings (Loss) Per Share of $(0.79) - PARSIPPANY, N.J., May 2, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 24 percent to $1.90 billion for the first quarter 2013, compared to $1.52 billion in the first quarter 2012. On a non-GAAP basis, diluted earnings per share for the first quarter 2013 was $1.99, compared to $1.64 per diluted share in the first quarter 2012, an increase of 21...

PARSIPPANY, N.J., and MONTREAL, May 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Actavis Specialty Brands (the "Company") has acquired worldwide rights to Valeant's Metronidazole 1.3% Vaginal Gel antibiotic development product, a topical antibiotic for the treatment of bacterial vaginosis. Under the terms of the agreement, Actavis Specialty Brands is acquiring the product for...

DUBLIN, April 29, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013 [http://www.researchandmarkets.com/research/rh9vld/pharmasphere ]" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Multinationals Threatening Domestic Growth of India's Generics Firms Previously considered a thorn in the side of Big Pharma,...

PARSIPPANY, N.J., April 26, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, today announced that it has entered into an agreement with Purdue Pharma to settle all outstanding patent litigation related to Actavis' generic version of the currently marketed abuse-deterrent formulation of OxyContin(®). Under the terms of the agreement, Actavis will be licensed to market a specified number of bottles of its generic OxyContin(®) beginning on...

PHILADELPHIA, April 25, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), announces that its subsidiary, Shire LLC, has settled all pending litigation with Actavis, Inc., Actavis LLC, and Actavis Elizabeth LLC (collectively "Actavis") and Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and ANDA, Inc. (collectively "Watson") in connection with Actavis' and Watson's Abbreviated New Drug Applications ("ANDAs") for generic versions of Shire's INTUNIV(R) ( guanfacine...